Ignite Creation Date:
2025-12-25 @ 4:18 AM
Ignite Modification Date:
2026-06-01 @ 6:53 AM
Study NCT ID:
NCT00057720
Status:
COMPLETED
Last Update Posted:
2011-07-25
First Post:
2003-04-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer
Sponsor:
Telik
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
TLK286.3017
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
Gail Brown, MD Chief Medical Officer
Old Organization:
Telik, Inc